Abstract: Fanconi anemia (FA) is an inherited chromosomal recessive syndrome characterized by cellular hypersensitivity to DNA crosslinking agents and bone marrow failure, which cause aplastic anemia, and an increased incidence of malignancy. 13 complementation groups are currently discovered, and 13 distinct genes have been cloned (FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, FNACI, FANCJ, FANCL, FANCM, FANCN).
INTRODUCTION
Fanconi anemia (FA) was first described by Swiss paediatrician Guido Fanconi in 1927 [1] [2] [3] . FA is an inherited chromosomal recessive syndrome characterized by bone marrow failure, which cause aplastic anemia, and an increased incidence of malignancy. FA occurred in 1 to 5 per million people and a carrier frequency of about 1 in 200 to 300 in most populations [2] . In Spain, 122 patients with FA were registered among about 40 million inhabitants. Due to founder effects and isolation, some populations have a higher prevalence of FA, for example, the Afrikaner population of South Africa [4] , the Ashkenazi Jewish population [5] , and the Spanish Gypsies [6] , with a carrier frequency of 1 in 77, 1 in 90, and 1 in 64 to 1 in 79 respectively. In a study of 754 patients, 80% experienced the onset of bone marrow failure( BMF), and 23% had neoplasms [7] . Most FA patients die of haematological diseases including bone marrow failure, myelodysplastic syndromes, and acute myelogenous leukemia. FA patients often die before 30 years of age [8] , the median survival time was 24 years [7] .
Cells from Fanconi anemia patients are sensitive to DNA cross-linking agents such as mitomycin C and diepoxybutane due to chromosomal instability, and it is the basis for a diagnosis test [3, 9] . FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCJ, FANCL, FANCM, FNACN [10, 11, 12] . Of the 13 genes, only FANCB is X chromosome-linked; the other 12 genes are autosomal genes [13] . Stem cells were first described by two Canadian scientists in 1963 [14] . Stem cells have the property of self-renewal and the potential to differentiate into different cell types. Stem cells act as a repair system for the body, and they are always ready to differentiates to the corresponding differentiated cells when there is a need throughout the life span, and they cope with the physiological changes inside the body, so as to keep a stable balance-homeostasis. There are two types of stem cells-embryonic stem cells and adult stem cells. Early embryonic stem cells can differentiate into all of the specialized embryonic tissues, whereas adult stem cells can only differentiate into cell types of the organ from which they originate, such as skin, hair, intestine, heart, bone or blood stem cells. The stem cells that form blood and immune cells are known as hematopoietic stem cells (HSC) [15] [16] [17] [18] .
Hematopoietic stem cell transplantation (HSCT) is the only proven useful cure for FA so far; by this method, a patient's defective stem cells are replaced by normal stem cells from a HLA matched donor. Locatelli F et al reported the outcome of 64 FA patients (age range, 2-20 years) who underwent HSCT in Italy, the 8-year estimate of overall survival rate was 87%, 69%, and 40% when the donors were HLA-identical siblings, HLA-partially matched relatives, and unrelated donors respectively (p<0.01) [19] . Unrelated donor is not suitable for transplantation because of higher risk of both acute and chronic graft-verse-host disease (GVHD) and transplant-related mortality (TRM) [20, 21] .
Fludarabine is a chemotherapy drug that is used for cancer therapy. It is most commonly used to treat chronic lymphocytic leukemia. By the combined use of fludarabine and T-cell depletion in recipients of unrelated donors, lower rates of GVHD, higher rates of hematopoietic recovery, and a significant improvement in both early and overall survival were achieved [20, 22, 23] .
Since it is not easy to find HLA-matched donors, gene therapy methods using viral vectors to deliver normal genes into patient's stem cells have been tried several years. Some genetic diseases such as Fanconi anemia probably could be treated by transferring correct genes into stem cells [24] . Viral vectors, such as adeno-associated virus vector [25] , retroviral vectors [26] [27] [28] [26, 34] . Lentiviral vectors are better than retroviral vectors because of their ability of transduction into early hematopoietic progenitors in vivo, and relatively higher transduction efficiency [35] .
Lentiviral vectors derived from human immunodeficiency virus type 1 (HIV-1) hold great hope for gene therapy. However, one of the safety concerns with the construction of retroviral and lentiviral packaging systems is the possibility of generating replication-competent retrovirus (RCR) and replication competent lentivirus (RCL) through genetic recombination between overlapping sequences respectively. In order to avoid this kind of possible hazards, modified lentiviral vectors have been developed [36, 37] .
Retroviral vectors randomly integrate at various positions in the cellular genome of stem cells, and there have been several reports and concerns of the integration of therapeutic vectors causing cancers [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] . This is a major hurdle and barrier for retroviral vectors being used as ideal vectors for gene therapy, and there is a real need to develop other safer vectors for gene therapy.
The FA primary BM cells in hypoplastic or aplastic marrow are limited and they are very fragile in vitro; the current gene transfer technology has many problems, physical or chemical methods are very toxic to stem cells [28, 45] . New ways aimed to target mutations at specific sites in the genome via homologous recombination have been tried for a few years. The frequency of homologous recombination in human cells is very low.
One promising method is the use of designed zinc-finger nucl-eases to target a specific defective gene and induce a double-strand break, and then this defective gene is repaired by stimulating homologous recombination between the chromosome and an extrachromosomal DNA donor. This strategy increased the frequency of homologous recombination repair remarkably [48] [49] [50] [51] [52] [53] .
Here I submit a possible new approach for stem cell gene therapy as briefly described in Fig. (1) .
This approach includes the following steps:
First, Genomic DNA is extracted from blood cells of a normal person. There are several genomic DNA extraction kits available now, such as PAXgene Blood DNA Kit from QIAGEN (http://www1.qiagen.com/Products/GenomicDna StabilizationPurification/PAXgeneBloodDNASystem/PAX geneBloodDNAKit.aspx?ShowInfo=1), this kit is used for purification of up to 500 μg genomic DNA from whole blood; and DNAzol® BD Reagent from Invitrogen (http:// tools.invitrogen.com/content/sfs/manuals/3898.pdf), typicallly 20-40 μg of genomic DNA can be obtained from 1 ml of whole blood by using this kit.
Second, the purified genomic DNA will be transferred into hematopoietic stem cells of a patient by microinjection [54] [55] [56] or transfection [32] in vitro. Transfection can be performed according to the instructions and protocols provided Fig. (1) . Hematopoietic Stem Cell Transplantation after Gene Correction by Invitrogen [https://resources.invitrogen.com/content/sfs/ manuals/11514015.pdf] after restriction endonuclease digestion [57] . Normal genes may also be synthesised by PCR method also [58, 59] ; the PCR product will be transfected into stem cells to replace mutated genes.
After homologous genetic recombination [60] [61] [62] [63] , the mutated genes of Fanconi anemia might be corrected. Finally, the gene-corrected hematopoietic stem cells are then transplanted into the same patient. Hopefully, the Fanconi anemia problems will be solved by this method.
DISCUSSION
Microinjection technique has been successfully used in transgenic animals [64] [65] [66] and in transferring foreign DNA clones into mammalian cells for several years [60, 67, 68] .
There was a report that 115Kb genomic DNA was transferred into human cells by an episomal vector and a genetic deficiency was corrected [69] . Herpes simplex virus type 1 (HSV-1) amplicons are plasmid-based viral vectors that lack viral coding sequences, therefore, these vectors are fully nontoxic for the infected cells. HSV-1 amplicons have been used to deliver >100 Kb complete genomic loci to rescue phenotypes in cellular models of genetic diseases [70] [71] [72] .
Fanconi anemia complementation test showed that after fusion of 2 different complementation groups of cells, mutated genes of Fanconi anemia could be repaired, so the hybrid cells were able to resist DNA cross-linking agents [2, 73, 74] . Somatic mosaicism, the presence of genetically distinct populations of somatic cells in a given organism due to in vivo reversion of a pathogenic allele to wild type has been described in several autosomal recessive disorders [75, 76] , such as hemophilia B [77] , Duchenne muscular dystrophy [78] , tyrosinemia type I [79], Bloom syndrome [80] , atypical X-linked severe combined immunodeficiency [81] , adenosine deaminase deficiency [82] , epidermolysis bullosa [83] , Wiskott-Aldrich syndrome [84, 85] , androgen insensi-tivity syndrome [86] , T-cell immunodeficiency [87] , leukocyte adhesion deficiency type 1 [88, 89] , and FA [90, 91] . Approximately 25% of patients with Fanconi anemia have evidence of somatic mosaicism, and two subpopulations of lymphocytes presence, one of which is hypersensitive to cross-linking agents while the other behaves normally in response to these agents [92] . Milder symptoms were often observed in FA patients with somatic mosaicism [91, 93] .
Several mechanisms have been proposed to account for somatic mosaicism, including back mutation, intragenic mitotic recombination, gene conversion, DNA polymerase slippage, and compensatory mutations in cis [3, 75, 76, 84, 90, 91, [93] [94] [95] .
It is very interesting that monozygotic twins with nonhematologic symptoms of FA due to somatic mosaics were discovered. A compensatory missense mutation was detected in the hematopoietic cells of both sisters, but not in their fibroblasts and their parents. Their skin fibroblasts were sensitive to DNA cross-linking agents, but not lymphocytes or committed hematopoietic progenitors. Both sisters have been free of hematologic symptoms for more than 28 years. It might be due to a single HSC in one twin that acquired a compensatory FANCA mutation, after many generations of cell replication, the corrected hematopoietic stem cells took over the defective ones, and resulting in both sisters gained normal blood cells, via the shared circulation exist in monozygotic twins. This kind of revertant mosaicism originally occurred in a stem cell is a way of natural stem cell gene therapy. It provided a successful model of stem cell gene therapy of FA in vivo, and it indicated that stem cell gene therapy is possible and the 1958 feasible [84, 91, 93] .
Homologous recombination was demonstrated in bacteria by Nobel Laureate Joshua Lederberg in 1958 [96, 97] . Homologous recombination can take place between any two DNA molecules that contain sequence homology. Homologous recombination can be divided into three key steps: strand exchange, branch migration and resolution. In E. coli, the key processes of homologous pairing and strand exchange are carried out by the protein RecA. RecA, ATP and singlestranded DNA (ssDNA) form a helical filament that binds to double-stranded DNA (dsDNA), searches for homology, and then catalyses the exchange of the complementary strand, producing a new heteroduplex [98, 99] . In yeast, the Rad51 protein has considerable structural and functional similarity to the bacterial RecA protein [98, 100] . In eukaryotes, homologus recombination commonly occurs during meiosis as chromosomal crossover between nonsister chromatids of two homologus pairs of chromosomes. This process leads to offspring having different combinations of genes from their parents and can produce new chimeric alleles, and hence create genetic diversity [98, [101] [102] [103] . Chromosomal crossovers also occur in asexual organisms and in somatic cells, since they are important in some forms of DNA repair [104] .
Gene targeting (gene knockout) as a result of homologous recombination between DNA sequences residing in the chromosome and newly introduced DNA sequences inserted into gene targeting vectors has been used to inactive (knockout) or modify/correct specific genes in mammalian cells for several years [61, 62, [105] [106] [107] [108] [109] [110] [111] . More than 11,000 genes in mice have been knocked out by using gene knockout technique [112] .
The frequency of gene targeting is unaffected by the length of nonhomologus DNA Sequences transferred to a target chromosomal locus [63] , so it is possible that large genomic DNA being used to correct defective genes.
Meganucleases are endonucleases, which recognize long ( >12 bp ) DNA target sites [113] . Meganucleases have been used to create site-specific DNA double-strand breaks (DSBs) and to induce efficient gene targeting [114] [115] [116] [117] [118] [119] .
Based on the above mentioned observations and experiments, it is very possible that by homologous genetic recombination as well as other unknown ways, injected normal genomic DNA could repair damaged or mutated genes, since the genomic DNA from a healthy donor has the correct genes and is very similar to the genomic DNA of a FA patient, although copy number variations contributed substantially to genomic differences among humans [120] [121] [122] .
We might inject normal genomic DNA or genomic DNA fragments into stem cells directly, instead of targeting genes inserted into vectors, so as to have a possible higher homologus recombination rate and/or lower random integration rate because of the highly compatible homologus sequences between humans, and therefore to have better gene therapy results. We may also combine the microinjection of genomic DNA and transfection of enzyme digested genomic DNA and/or PCR synthesized targeting genes together, to get more efficient gene correction by homologous genetic recombination.
The major unsolved problem for bone marrow transplantation and HSCT is that it is often very difficult to find suitable human leukocyte antigen (HLA)-matched donors for most of the patients [123] [124] [125] . Graft failure, graft-versushost disease (GVHD) and opportunistic infections were often occurred in FA patients after HSCT.
HSCT with donors other than HLA-identical siblings is associated with high morbidity and poor survival [8, 21, 22, 126, 127] . Up to now, the only practical and proven cure for Fanconi anemia-associated bone marrow failure is successful allogeneic HSCT. Cells seem to tolerate large foreign DNA without immunological rejection; therefore, it is possible that normal genomic DNA is transferred into stem cells from patients and to correct the defective genes via homologus genetic recombination without any immunological rejection. This could be the major benefit of the new strategy. It is a relatively simple but meaningful method that human normal genomic DNA is considered as materials for homologous genetic recombination to repair defective genes in vivo.
When 30 purified mouse stem cells were transferred, 50% lethally irradiated mice survived for more than 30 days [15] . A few corrected HSCs should be capable of repopulating the bone marrow and blood of an affected FA patient [32, 93] . Accordingly, we might only need hundreds of genecorrected stem cells significantly to improve a patient's physiological condition. If this scheme works at cellular and animal experimental level, further experimental therapies might be considered for patients; hopefully we might have a cure for Fanconi anemia and many other genetic diseases like cystic fibrosis [128] , Huntington's disease [129, 130] , and muscular dystrophy [131] [132] [133] in the near future. 
